However, the application of intratumoralinjections is limited to certain tumor types and the wide spectrumof patient characteristics motivates the development of alternativetumor-targeting strategies.54,55 In certain settings,tumor biology can be exploited for specific targeting of the payload,for example, by using SQT01 to target HER2-positive tumors such asthose occurring in breast cancer, non-small-cell lung cancer, andgastric cancer. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.